4D Molecular Therapeutics (FDMT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

4D Molecular Therapeutics Revenue Highlights

Main Segment (Y)

Collaboration And License Revenue

Main Geography (Y)

UNITED STATES

4D Molecular Therapeutics Revenue by Period

4D Molecular Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	-	-100.00%
2022-12-31	$3.13M	-82.65%
2021-12-31	$18.04M	32.52%
2020-12-31	$13.61M	94.85%
2019-12-31	$6.99M	-50.56%
2018-12-31	$14.13M	144.04%
2017-12-31	$5.79M	-

4D Molecular Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

4D Molecular Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	-	-100.00%
2024-06-30	$5.00K	-82.14%
2024-03-31	$28.00K	-247.37%
2023-12-31	$-19.00K	-100.09%
2023-09-30	$20.20M	8353.56%
2023-06-30	$239.00K	-19.80%
2023-03-31	$298.00K	-76.10%
2022-12-31	$1.25M	149.40%
2022-09-30	$500.00K	208.64%
2022-06-30	$162.00K	-86.71%
2022-03-31	$1.22M	1225.00%
2021-12-31	$92.00K	-93.27%
2021-09-30	$1.37M	-90.63%
2021-06-30	$14.58M	629.00%
2021-03-31	$2.00M	-304.71%
2020-12-31	$-977.00K	-113.17%
2020-09-30	$7.42M	104.27%
2020-06-30	$3.63M	2.77%
2020-03-31	$3.54M	74.14%
2019-12-31	$2.03M	275.93%
2019-09-30	$540.00K	-75.54%
2019-06-30	$2.21M	-
2019-03-31	$2.21M	-51.26%
2018-12-31	$4.53M	-
2018-09-30	$4.53M	78.75%
2018-06-30	$2.53M	-
2018-03-31	$2.53M	-

4D Molecular Therapeutics generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

4D Molecular Therapeutics Revenue Breakdown

4D Molecular Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20
Collaboration And License Revenue	$20.01M	$3.13M	$18.04M	$13.61M

4D Molecular Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration And License Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Collaboration And License Revenue	$3.00K	$28.00K	-	$20.01M	$239.00K	$298.00K	$1.25M	$500.00K	$162.00K	$1.22M	$12.00K	$64.00K	$14.58M	$2.00M

4D Molecular Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration And License Revenue (100.00%).

4D Molecular Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20
NETHERLANDS	$567.00K	$3.09M	$736.00K	$742.00K
UNITED STATES	$20.16M	$35.00K	$121.00K	$-27.00K
SWITZERLAND	-	-	$17.18M	$12.90M
AUSTRALIA	-	-	-	-

4D Molecular Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (97.26%), and NETHERLANDS (2.74%).

Quarterly Revenue by Country

Country	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
UNITED STATES	$3.00K	$28.00K	-	$20.16M	$9.00K	$3.00K	$2.00K	$3.00K	$2.00K	$28.00K	$89.00K	$12.00K	$16.00K	$3.00K
NETHERLANDS	-	-	$1.00K	$41.00K	$230.00K	$295.00K	$1.25M	$497.00K	$160.00K	$1.19M	$12.00K	$64.00K	$267.00K	$392.00K
SWITZERLAND	-	-	-	-	-	-	-	-	-	-	$-9.00K	$1.29M	$14.30M	$1.60M

4D Molecular Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (100.00%).

4D Molecular Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RVMD	Revolution Medicines	$11.58M	-
STOK	Stoke Therapeutics	$8.78M	$4.89M
KRON	Kronos Bio	$6.29M	$2.37M
IPSC	Century Therapeutics	$2.23M	$791.00K
LYRA	Lyra Therapeutics	$1.56M	$195.00K
CGEM	Cullinan Oncology	-	-
BDTX	Black Diamond Therapeutics	-	-
CCCC	C4 Therapeutics	-	-
GOSS	Gossamer Bio	-	$9.48M
REPL	Replimune Group	-	-
PASG	Passage Bio	-	-
BMEA	Biomea Fusion	-	-
MLYS	Mineralys Therapeutics	-	-
NVCT	Nuvectis Pharma	-	-
AKRO	Akero Therapeutics	-	-
FDMT	4D Molecular Therapeutics	-	-
EWTX	Edgewise Therapeutics	-	-

FDMT Revenue FAQ

What is 4D Molecular Therapeutics’s yearly revenue?

4D Molecular Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $3.13M, representing a decrease of -82.65% compared to 2021. FDMT's yearly revenue for 2021 was $18.04M, representing an increase of 32.52% compared to 2020.

What is 4D Molecular Therapeutics’s quarterly revenue?

4D Molecular Therapeutics's quarterly revenue for Q3 2024 was $0, a -100.00% decrease from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $5K, a -82.14% decrease from the previous quarter (Q1 2024), and a -97.91% decrease year-over-year (Q2 2023). FDMT's quarterly revenue for Q1 2024 was $28K, a -247.37% decrease from the previous quarter (Q4 2023), and a -90.60% decrease year-over-year (Q1 2023).

What is 4D Molecular Therapeutics’s revenue growth rate?

4D Molecular Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.

What are 4D Molecular Therapeutics’s revenue streams?

4D Molecular Therapeutics's revenue streams in c 23 are Collaboration And License Revenue

What is 4D Molecular Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of 4D Molecular Therapeutics was Collaboration And License Revenue. This segment made a revenue of $20.01M, representing 100.00% of the company's total revenue.